Details:
Forxiga (dapagliflozin) is an inhibitor of SGLT2. By inhibiting SGLT2, which is investigated for the treatment of children and adolescents with type 2 diabetes.
Lead Product(s): Dapagliflozin
Therapeutic Area: Endocrinology Product Name: Forxiga
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 04, 2023
Details:
The partnership aims at addressing the pressing global issue of hypogonadism through the launch of a comprehensive Early Access Program for Kyzatrex (testosterone undecanoate), a proprietary softgel oral formulation absorbed primarily via the lymphatic system.
Lead Product(s): Testosterone Undecanoate
Therapeutic Area: Endocrinology Product Name: Kyzatrex
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Marius Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership August 10, 2023
Details:
Xigduo XR (dapagliflozin and metformin hydrochloride extended-release) tablet is a sodium-glucose cotransporter 2 inhibitor a once-daily fixed-dose combination, has been approved for type-2 diabetes.
Lead Product(s): Dapagliflozin,Metformin
Therapeutic Area: Endocrinology Product Name: Xigduo XR
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2023
Details:
Ogluo® is a ready-to-use, ambiently stored, preparation of glucagon that has been specifically designed for patients living with diabetes with severe hypoglycaemia.
Lead Product(s): Glucagon
Therapeutic Area: Endocrinology Product Name: Ogluo
Highest Development Status: Approved Product Type: Peptide
Partner/Sponsor/Collaborator: Arecor
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 12, 2022
Details:
Under the terms of the proposed acquisition, Arecor Therapeutics has agreed to acquire Tetris Pharma and will continue to commercialize Ogluo in the UK and EEA. Gvoke® (US) /Ogluo® (EU), the first prescription, ready-to-use, pre-mixed, pre-measured glucagon injection.
Lead Product(s): Glucagon
Therapeutic Area: Endocrinology Product Name: Ogluo
Highest Development Status: Approved Product Type: Peptide
Partner/Sponsor/Collaborator: Arecor
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition August 01, 2022
Details:
BYDUREON BCise brings an important new therapeutic option to physicians caring for children with this chronic disease that can lead to serious long-term issues if not adequately treated.
Lead Product(s): Exenatide
Therapeutic Area: Endocrinology Product Name: Bydureon
Highest Development Status: Approved Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 23, 2021
Details:
Data at week 24 also showed that exenatide once weekly was generally well tolerated and consistent with the existing safety profile in adults. Phase III trial met primary endpoint, significantly reducing blood sugar (HbA1c) versus placebo.
Lead Product(s): Exenatide
Therapeutic Area: Endocrinology Product Name: Bydureon
Highest Development Status: Approved Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 25, 2021
Details:
AstraZeneca India has granted rights to Sun Pharma to promote and distribute Dapagliflozin under the brand name Oxra. Sun Pharma also gained the rights to promote and distribute the Oxramet (Dapagliflozin + Metformin) and Oxraduo (Dapagliflozin + Saxagliptin).
Lead Product(s): Dapagliflozin Propanediol Monohydrate
Therapeutic Area: Endocrinology Product Name: Oxra
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Sun Pharmaceutical Industries Limited
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition May 28, 2021
Details:
Eton Pharmaceuticals Canadian rights to ALKINDI® SPRINKLE from Diurnal Group plc. Eton Pharmaceuticals currently commercializes ALKINDI® SPRINKLE in the United States as a replacement therapy for Adrenocortical Insufficiency (AI) in children under 17 years of age.
Lead Product(s): Hydrocortisone
Therapeutic Area: Endocrinology Product Name: Alkindi Sprinkle
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Eton Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition January 14, 2021
Details:
Under the terms of the agreement EffRx has received the exclusive rights to register and commercialize Alkindi® in Switzerland.
Lead Product(s): Hydrocortisone
Therapeutic Area: Endocrinology Product Name: Alkindi Sprinkle
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: EffRx
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 21, 2020